Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG reports news on a late-stage ophthalmology and neuro-ophthalmology pipeline focused on eye and optic-nerve disorders with unmet medical need. Company updates commonly cover OCS-01 eye drops for diabetic macular edema, Privosegtor for optic neuritis and other optic neuropathies, and Licaminlimab, a topical anti-TNFα candidate being developed for dry eye disease with a genotype-based approach.
Recurring developments include clinical-program updates, FDA and EMA regulatory interactions, scientific meeting presentations, pipeline reviews, financial results, capital-market communications, annual general meeting materials, and notifications of managerial transactions. Oculis is a Swiss biopharmaceutical company with ordinary shares traded on Nasdaq and Nasdaq Iceland under OCS.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Oculis has established its US headquarters in Boston, MA, enhancing its presence in the biotech hub as part of its strategy following its NASDAQ listing (OCS). This new office will facilitate operations and upcoming clinical milestones, including results from the Phase 3 DIAMOND study of OCS-01 for diabetic macular edema (DME) and the OPTIMIZE study for inflammation and pain post-cataract surgery later in 2023. Additionally, Oculis has bolstered its finance and development team with the hiring of Dr. Fang Li as Senior Vice President of Regulatory Affairs, who brings over 25 years of experience in drug approvals in ophthalmology. Oculis aims to leverage Boston's innovation ecosystem to support its operations and clinical development.
Oculis Holding AG (Nasdaq: OCS) announced management participation in two key investor conferences in April 2023. The first is the 22nd Annual Needham Virtual Healthcare Conference on April 20, where they will present from 8:45 to 9:25 AM ET. A live webcast will be available on the Oculis website. The second event is the 16th Annual Kempen Life Sciences Conference in Amsterdam, scheduled for April 25, 2023, featuring investor meetings. Oculis focuses on innovative treatments for eye care, with a pipeline that includes candidates for diabetic macular edema and dry eye disease.
Oculis Holding AG (Nasdaq: OCS) will hold a virtual conference call on April 13, 2023, from 8:00 am to 9:00 am ET to discuss its late-stage pipeline and clinical milestones. The company focuses on addressing significant medical needs in eye care, particularly in diabetic macular edema and dry eye disease. Oculis expects Stage 1 results from its Phase 3 DIAMOND study of OCS-01 later this year and plans to initiate two Phase 2 studies of OCS-02. Leading retina and anterior segment experts will participate in a Q&A session. A live audio webcast will be available on the company's website, with replay access for 30 days post-event.
Summary not available.
Oculis Holding AG (NASDAQ: OCS) has completed enrollment in its Phase 3 OPTIMIZE trial for OCS-01, a novel topical corticosteroid aimed at treating inflammation and pain post-ocular surgery. The trial involves 240 patients at 25 locations in the U.S., focusing on reducing inflammation by Day 15 and pain by Day 4. If approved, OCS-01 could be the first once-daily, preservative-free corticosteroid for this purpose. Additional results from the Phase 3 DIAMOND trial for diabetic macular edema (DME) are also anticipated later this year, hinting at further advancements in ocular treatments.